Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
FDA approves treatment for people with mild forms of Alzheimer's
03:59pm, Saturday, 07'th Jan 2023 MarketWatch
Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year
FDA approves Biogen, Eisai Alzheimer's drug
07:10pm, Friday, 06'th Jan 2023
An Alzheimer's drug from Biogen and Eisai has received accelerated approval from the Food and Drug Administration, the companies and agency announced Friday.
FDA approves Biogen-Eisai Alzheimer's drug, China in talks to make Pfizer Paxlovid generic
05:33pm, Friday, 06'th Jan 2023
Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's plans to distribute Pfizer's Paxlovid pill.
FDA approves Biogen's Alzheimer's drug
02:59pm, Friday, 06'th Jan 2023
CNBC's Meg Tirrell reports on Biogen and the company receiving FDA approval for an Alzheimer's treatment.
1 Stock Defying the Downturn to Buy, and 1 to Avoid
02:53pm, Friday, 06'th Jan 2023 The Motley Fool
These two stocks might go in different directions in the future.
FDA approves treatment for people with mild forms of Alzheimer's
02:41pm, Friday, 06'th Jan 2023
The Food and Drug Administration on Friday granted an accelerated approval to Eisai and Biogen's Alzheimer's disease treatment, which showed in clinical trials that it can slow the progression of the
FDA Approves Eisai and Biogen's New Alzheimer's Therapy
02:37pm, Friday, 06'th Jan 2023
The Food and Drug Administration on Friday approved Eisai and Biogen's Alzheimer's treatment lecanemab, clearing the way for the drug to be prescribed to patients and opening what will likely be a lon
The FDA just approved a new Alzheimer's drug that's set to be a blockbuster
02:21pm, Friday, 06'th Jan 2023
The new drug, called Leqembi, slowed the rate of cognitive decline in Alzheimer's patients by 27%.
FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial
02:11pm, Friday, 06'th Jan 2023
The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer's.
Jefferies' Michael Yee on Biogen as FDA could be on the verge of approving Alzheimer's drug
02:09pm, Friday, 06'th Jan 2023
Michael Yee, Jefferies managing director, joins 'The Exchange' to discuss biotech and the FDA's looming decision on Biogen's second Alzheimer's drug.
Lecanemab Alert: What Would Alzheimer's Drug Approval Mean for Biogen (BIIB) Stock?
02:07pm, Friday, 06'th Jan 2023
One stock that's trading in the right direction today is prominent mega-cap biotech stock Biogen (NASDAQ: BIIB ). Shares of BIIB stock have surged around 3.7% as of early afternoon trading on appare
Should iShares Morningstar MidCap Value ETF (IMCV) Be on Your Investing Radar?
11:20am, Friday, 06'th Jan 2023 Zacks Investment Research
Style Box ETF report for IMCV
Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?
10:41am, Friday, 06'th Jan 2023
Biogen stock jumped Friday ahead of an FDA decision on the accelerated approval of its experimental Alzheimer's treatment, lecanemab. The post Biogen Could Get A Second Alzheimer's OK — But Will Wil
1 Stock Defying the Downturn to Buy, and 1 to Avoid
09:53am, Friday, 06'th Jan 2023
These two stocks might go in different directions in the future.
Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments
08:46am, Friday, 06'th Jan 2023
CNBC's Meg Tirrell joins 'Squawk Box' to discuss the big day ahead for Alzheimer's medicine.
